Sutro Biopharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2022

Summary of Computation of Company's Basic and Diluted Net Loss Per Share

The following table sets forth the computation of the Company’s basic and diluted net loss per share.


	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2022			2021			2022			2021
	(in thousands, except share and per share amounts)
Numerator:
Net loss	$	(26,012	)	$	(6,152	)	$	(65,122	)	$	(36,511	)
Denominator:
Shares used in computing net loss per share		46,957,196			46,116,175			46,729,663			46,007,892
Net loss per share, basic and diluted	$	(0.55	)	$	(0.13	)	$	(1.39	)	$	(0.79	)

Summary of Common Stock Equivalents of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share

The following common stock equivalents were excluded from the computation of diluted net loss per share for the period ended June 30, 2022 and 2021, because including them would have been antidilutive:


	As of June 30,
	2022		2021
Common stock options issued and outstanding		7,507,431		6,250,931
Restricted stock units issued and outstanding		3,737,945		1,988,426
Warrants to purchase common stock		127,616		153,070
Employee stock purchase plan		158,299		36,902
Total		11,531,291		8,429,329